About Actimed
Pipeline
Cachexia
News & Events
Contact
NEWS
Feb 2, 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Dec 1, 2020
Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia
Management Team and Board
David Ebsworth
Chairman
Robin Bhattacherjee
Chief Executive Officer
Andrew J. Stewart Coats
Founder and Non-Executive Director
Frank Misselwitz
Chief Medical Officer and Non-executive Director
Stefan Wohlfeil
Non-executive Director
Hugh Jackson
Chief Financial Officer